Shelton Capital Management lowered its holdings in shares of Shire PLC (NASDAQ:SHPG) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,943 shares of the biopharmaceutical company’s stock after selling 1,243 shares during the quarter. Shelton Capital Management’s holdings in Shire were worth $2,783,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the stock. Commerzbank Aktiengesellschaft FI boosted its stake in Shire by 22.1% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 375 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Shire by 6.2% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 381 shares during the last quarter. Pitcairn Co. boosted its stake in Shire by 26.5% during the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 401 shares during the last quarter. Thompson Investment Management Inc. boosted its stake in Shire by 5.2% during the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock valued at $1,438,000 after buying an additional 468 shares during the last quarter. Finally, Verition Fund Management LLC boosted its stake in Shire by 18.9% during the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 472 shares during the last quarter. Hedge funds and other institutional investors own 20.74% of the company’s stock.
Shire PLC (SHPG) traded up $2.44 during trading hours on Friday, hitting $135.30. The stock had a trading volume of 923,300 shares, compared to its average volume of 1,487,487. Shire PLC has a 1-year low of $123.73 and a 1-year high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The company has a market cap of $40,320.00, a price-to-earnings ratio of 6.16, a price-to-earnings-growth ratio of 0.74 and a beta of 1.41.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.75% and a net margin of 28.17%. The firm had revenue of $4.14 billion during the quarter. During the same period in the prior year, the business posted $3.37 earnings per share. Shire’s revenue was up 8.9% on a year-over-year basis. analysts expect that Shire PLC will post 15.31 earnings per share for the current year.
SHPG has been the subject of a number of research reports. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. FBR & Co began coverage on Shire in a research note on Thursday, October 19th. They set a “buy” rating and a $201.00 price target for the company. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada lowered their price objective on Shire to $181.00 and set an “outperform” rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $209.23.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/16/shire-plc-shpg-shares-sold-by-shelton-capital-management.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.